NCT07159243View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

All Listed Sponsors
lead

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

INDUSTRY